Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Retinoic acid receptor signalling directly regulates osteoblast and adipocyte differentiation from mesenchymal progenitor cells.

Green AC, Kocovski P, Jovic T, Walia MK, Chandraratna RAS, Martin TJ, Baker EK, Purton LE.

Exp Cell Res. 2017 Jan 1;350(1):284-297. doi: 10.1016/j.yexcr.2016.12.007. Epub 2016 Dec 10.

PMID:
27964926
2.

Treatment with retinoid X receptor agonist IRX4204 ameliorates experimental autoimmune encephalomyelitis.

Chandraratna RA, Noelle RJ, Nowak EC.

Am J Transl Res. 2016 Feb 15;8(2):1016-26. eCollection 2016.

3.

Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.

Wang J, Bi W, Zhao W, Varghese M, Koch RJ, Walker RH, Chandraratna RA, Sanders ME, Janesick A, Blumberg B, Ward L, Ho L, Pasinetti GM.

Oncotarget. 2016 Feb 16;7(7):7469-79. doi: 10.18632/oncotarget.7191.

4.

RARγ is a negative regulator of osteoclastogenesis.

Green AC, Poulton IJ, Vrahnas C, Häusler KD, Walkley CR, Wu JY, Martin TJ, Gillespie MT, Chandraratna RA, Quinn JM, Sims NA, Purton LE.

J Steroid Biochem Mol Biol. 2015 Jun;150:46-53. doi: 10.1016/j.jsbmb.2015.03.005. Epub 2015 Mar 20.

PMID:
25800721
5.

Active repression by RARγ signaling is required for vertebrate axial elongation.

Janesick A, Nguyen TT, Aisaki K, Igarashi K, Kitajima S, Chandraratna RA, Kanno J, Blumberg B.

Development. 2014 Jun;141(11):2260-70. doi: 10.1242/dev.103705. Epub 2014 May 12.

6.

Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration.

Aoyama K, Saha A, Tolar J, Riddle MJ, Veenstra RG, Taylor PA, Blomhoff R, Panoskaltsis-Mortari A, Klebanoff CA, Socié G, Munn DH, Murphy WJ, Serody JS, Fulton LM, Teshima T, Chandraratna RA, Dmitrovsky E, Guo Y, Noelle RJ, Blazar BR.

Blood. 2013 Sep 19;122(12):2125-34. doi: 10.1182/blood-2012-11-470252. Epub 2013 Jun 27.

7.

A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells.

Guo Y, Pino-Lagos K, Ahonen CA, Bennett KA, Wang J, Napoli JL, Blomhoff R, Sockanathan S, Chandraratna RA, Dmitrovsky E, Turk MJ, Noelle RJ.

Cancer Res. 2012 Oct 15;72(20):5230-9. doi: 10.1158/0008-5472.CAN-12-1727. Epub 2012 Aug 17.

8.

A retinoic acid-dependent checkpoint in the development of CD4+ T cell-mediated immunity.

Pino-Lagos K, Guo Y, Brown C, Alexander MP, Elgueta R, Bennett KA, De Vries V, Nowak E, Blomhoff R, Sockanathan S, Chandraratna RA, Dmitrovsky E, Noelle RJ.

J Exp Med. 2011 Aug 29;208(9):1767-75. doi: 10.1084/jem.20102358. Epub 2011 Aug 22.

9.

Retinoic acid receptor signaling regulates choroid fissure closure through independent mechanisms in the ventral optic cup and periocular mesenchyme.

Lupo G, Gestri G, O'Brien M, Denton RM, Chandraratna RA, Ley SV, Harris WA, Wilson SW.

Proc Natl Acad Sci U S A. 2011 May 24;108(21):8698-703. doi: 10.1073/pnas.1103802108. Epub 2011 May 9.

10.

Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists.

Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C, Chandraratna RA, Mishina Y, Enomoto-Iwamoto M, Pacifici M, Iwamoto M.

Nat Med. 2011 Apr;17(4):454-60. doi: 10.1038/nm.2334. Epub 2011 Apr 3. Erratum in: Nat Med. 2012 Oct;18(10):1592.

11.

Growth differentiation factor 11 signaling controls retinoic acid activity for axial vertebral development.

Lee YJ, McPherron A, Choe S, Sakai Y, Chandraratna RA, Lee SJ, Oh SP.

Dev Biol. 2010 Nov 1;347(1):195-203. doi: 10.1016/j.ydbio.2010.08.022. Epub 2010 Aug 27.

12.

Retinoid signalling is required for information transfer from mesoderm to neuroectoderm during gastrulation.

Lloret-Vilaspasa F, Jansen HJ, de Roos K, Chandraratna RA, Zile MH, Stern CD, Durston AJ.

Int J Dev Biol. 2010;54(4):599-608. doi: 10.1387/ijdb.082705fl.

13.

Inhibition of ectopic bone formation by a selective retinoic acid receptor alpha-agonist: a new therapy for heterotopic ossification?

Shimono K, Morrison TN, Tung WE, Chandraratna RA, Williams JA, Iwamoto M, Pacifici M.

J Orthop Res. 2010 Feb;28(2):271-7. doi: 10.1002/jor.20985.

14.

Integrities of A/B and C domains of RXR are required for rexinoid-induced caspase activations and apoptosis.

Qin S, Okawa Y, Atangan LI, Brown G, Chandraratna RA, Zhao Y.

J Steroid Biochem Mol Biol. 2008 Nov;112(1-3):25-31. doi: 10.1016/j.jsbmb.2008.08.001. Epub 2008 Aug 9.

PMID:
18761406
15.

Mechanism of asymmetric ovarian development in chick embryos.

Ishimaru Y, Komatsu T, Kasahara M, Katoh-Fukui Y, Ogawa H, Toyama Y, Maekawa M, Toshimori K, Chandraratna RA, Morohashi K, Yoshioka H.

Development. 2008 Feb;135(4):677-85. doi: 10.1242/dev.012856. Epub 2008 Jan 16.

16.

A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland.

Liby K, Royce DB, Risingsong R, Williams CR, Wood MD, Chandraratna RA, Sporn MB.

Clin Cancer Res. 2007 Oct 15;13(20):6237-43.

17.

Granulocyte colony-stimulating factor and an RARalpha specific agonist, VTP195183, synergize to enhance the mobilization of hematopoietic progenitor cells.

Herbert KE, Walkley CR, Winkler IG, Hendy J, Olsen GH, Yuan YD, Chandraratna RA, Prince HM, Lévesque JP, Purton LE.

Transplantation. 2007 Feb 27;83(4):375-84.

PMID:
17318068
19.

Retinoic acid signaling is essential for formation of the heart tube in Xenopus.

Collop AH, Broomfield JA, Chandraratna RA, Yong Z, Deimling SJ, Kolker SJ, Weeks DL, Drysdale TA.

Dev Biol. 2006 Mar 1;291(1):96-109. Epub 2006 Jan 19.

20.

Retinoid x receptor agonists increase bcl2a1 expression and decrease apoptosis of naive T lymphocytes.

Rasooly R, Schuster GU, Gregg JP, Xiao JH, Chandraratna RA, Stephensen CB.

J Immunol. 2005 Dec 15;175(12):7916-29.

21.

Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors.

Li X, Hansen PA, Xi L, Chandraratna RA, Burant CF.

J Biol Chem. 2005 Nov 18;280(46):38317-27. Epub 2005 Sep 22.

23.
25.

A novel transglutaminase activator forms a complex with type 1 transglutaminase.

Sturniolo MT, Chandraratna RA, Eckert RL.

Oncogene. 2005 Apr 21;24(18):2963-72.

PMID:
15846304
26.

Differential regulation of sodium/iodide symporter gene expression by nuclear receptor ligands in MCF-7 breast cancer cells.

Kogai T, Kanamoto Y, Li AI, Che LH, Ohashi E, Taki K, Chandraratna RA, Saito T, Brent GA.

Endocrinology. 2005 Jul;146(7):3059-69. Epub 2005 Apr 7.

PMID:
15817668
27.

Dorsoventral patterning of the Xenopus eye: a collaboration of Retinoid, Hedgehog and FGF receptor signaling.

Lupo G, Liu Y, Qiu R, Chandraratna RA, Barsacchi G, He RQ, Harris WA.

Development. 2005 Apr;132(7):1737-48.

28.

Retinoid-related molecule AGN193198 potently induces G2M arrest and apoptosis in bladder cancer cells.

Reitmair A, Shurland DL, Tsang KY, Chandraratna RA, Brown G.

Int J Cancer. 2005 Jul 20;115(6):917-23.

29.
30.

Global analysis of RAR-responsive genes in the Xenopus neurula using cDNA microarrays.

Arima K, Shiotsugu J, Niu R, Khandpur R, Martinez M, Shin Y, Koide T, Cho KW, Kitayama A, Ueno N, Chandraratna RA, Blumberg B.

Dev Dyn. 2005 Feb;232(2):414-31.

31.

Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor, and liver X receptor in mouse liver.

Anderson SP, Dunn C, Laughter A, Yoon L, Swanson C, Stulnig TM, Steffensen KR, Chandraratna RA, Gustafsson JA, Corton JC.

Mol Pharmacol. 2004 Dec;66(6):1440-52. Epub 2004 Sep 15.

PMID:
15371561
33.

Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors.

Corton JC, Apte U, Anderson SP, Limaye P, Yoon L, Latendresse J, Dunn C, Everitt JI, Voss KA, Swanson C, Kimbrough C, Wong JS, Gill SS, Chandraratna RA, Kwak MK, Kensler TW, Stulnig TM, Steffensen KR, Gustafsson JA, Mehendale HM.

J Biol Chem. 2004 Oct 29;279(44):46204-12. Epub 2004 Aug 9.

34.

Retinoic acid receptor antagonist inhibits CD38 antigen expression on human hematopoietic cells in vitro.

Prus E, Chandraratna RA, Fibach E.

Leuk Lymphoma. 2004 May;45(5):1025-35.

PMID:
15291363
35.

Activation by retinoids of the uncoupling protein UCP1.

Tomás P, Jiménez-Jiménez J, Zaragoza P, Vuligonda V, Chandraratna RA, Rial E.

Biochim Biophys Acta. 2004 Jul 23;1658(1-2):157-64.

36.

An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium.

Keedwell RG, Zhao Y, Hammond LA, Wen K, Qin S, Atangan LI, Shurland DL, Wallace DM, Bird R, Reitmair A, Chandraratna RA, Brown G.

Br J Cancer. 2004 Aug 2;91(3):580-8.

37.

Independent roles for retinoic acid in segmentation and neuronal differentiation in the zebrafish hindbrain.

Linville A, Gumusaneli E, Chandraratna RA, Schilling TF.

Dev Biol. 2004 Jun 1;270(1):186-99.

38.

Casein kinase 1alpha interacts with retinoid X receptor and interferes with agonist-induced apoptosis.

Zhao Y, Qin S, Atangan LI, Molina Y, Okawa Y, Arpawong HT, Ghosn C, Xiao JH, Vuligonda V, Brown G, Chandraratna RA.

J Biol Chem. 2004 Jul 16;279(29):30844-9. Epub 2004 May 6.

39.

Multiple points of interaction between retinoic acid and FGF signaling during embryonic axis formation.

Shiotsugu J, Katsuyama Y, Arima K, Baxter A, Koide T, Song J, Chandraratna RA, Blumberg B.

Development. 2004 Jun;131(11):2653-67. Epub 2004 May 5.

40.

A retinoid-related molecule that does not bind to classical retinoid receptors potently induces apoptosis in human prostate cancer cells through rapid caspase activation.

Keedwell RG, Zhao Y, Hammond LA, Qin S, Tsang KY, Reitmair A, Molina Y, Okawa Y, Atangan LI, Shurland DL, Wen K, Wallace DM, Bird R, Chandraratna RA, Brown G.

Cancer Res. 2004 May 1;64(9):3302-12.

41.

Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid.

Balasubramanian S, Chandraratna RA, Eckert RL.

Carcinogenesis. 2004 Aug;25(8):1377-85. Epub 2004 Feb 19.

PMID:
14976133
42.

Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids.

Hellemans K, Verbuyst P, Quartier E, Schuit F, Rombouts K, Chandraratna RA, Schuppan D, Geerts A.

Hepatology. 2004 Jan;39(1):97-108.

PMID:
14752828
43.

Identification of the molecular requirements for an RAR alpha-mediated cell cycle arrest during granulocytic differentiation.

Walkley CR, Purton LE, Snelling HJ, Yuan YD, Nakajima H, Chambon P, Chandraratna RA, McArthur GA.

Blood. 2004 Feb 15;103(4):1286-95. Epub 2003 Oct 23.

44.

A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase.

Sturniolo MT, Dashti SR, Deucher A, Rorke EA, Broome AM, Chandraratna RA, Keepers T, Eckert RL.

J Biol Chem. 2003 Nov 28;278(48):48066-73. Epub 2003 Aug 19.

46.

BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect.

Hallahan AR, Pritchard JI, Chandraratna RA, Ellenbogen RG, Geyer JR, Overland RP, Strand AD, Tapscott SJ, Olson JM.

Nat Med. 2003 Aug;9(8):1033-8. Epub 2003 Jul 20.

PMID:
12872164
47.

Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway.

Xiao JH, Ghosn C, Hinchman C, Forbes C, Wang J, Snider N, Cordrey A, Zhao Y, Chandraratna RA.

J Biol Chem. 2003 Aug 8;278(32):29954-62. Epub 2003 May 27.

49.

Effects of retinoid ligands on RIP140: molecular interaction with retinoid receptors and biological activity.

Farooqui M, Franco PJ, Thompson J, Kagechika H, Chandraratna RA, Banaszak L, Wei LN.

Biochemistry. 2003 Feb 4;42(4):971-9.

PMID:
12549917
50.

The prospects of retinoids in the treatment of prostate cancer.

Hammond LA, Brown G, Keedwell RG, Durham J, Chandraratna RA.

Anticancer Drugs. 2002 Sep;13(8):781-90. Review. Erratum in: Anticancer Drugs. 2002 Nov;13(10):1077-8.

PMID:
12394261

Supplemental Content

Loading ...
Support Center